Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai has released Phase III EMBRACE study (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus Eribulin E7389) results which showed that Eribulin Mesylate improved median overall survival (OS) compared with Treatment of Physician's Choice (TPC) in heavily pre-treated metastatic breast cancer patients.
Subscribe to our email newsletter
The results of the study were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting as part of an ASCO-sponsored press briefing.
Eisai said that the Phase III EMBRACE study was an open-label, randomised, multi-center study of 762 patients with locally recurrent or metastatic breast cancer who were previously treated with at least two and a maximum of five prior chemotherapies, including an anthracycline and a taxane.
Eisai’s EMBRACE study results met its primary endpoint of overall survival, showing that patients who received eribulin survived a median of 2.5 months longer than patients who received TPC.
Chris Twelves, lead investigator for the EMBRACE study and professor of clinical cancer pharmacology and oncology from the University of Leeds and university hospital of St James, Leeds, UK, said: “These results showed that Eribulin improved overall survival versus a variety of agents used in a real-world setting.”